Youareaskedtoundertakeareview of heart failure prescribinq incomparisontocuinicat auidelines withinthe
HospitauTrust.Youareexamininqevidencefortheuseof aldosteroneantaaonists inthetreatment of heart
faiture.
TheRandomisedAldactoneEvaluationStudy RALES)triaudemonstratedthat addingthealdosterone
antagonistspironolactonetoan angiotensin-converting enzyme(ACE) inhibitor reduced allrcause mortality by
30(RRO70,95CI0.606to0.82;p<0.001;ARR11%
Accordinqtothesefiqures,whatisthenumber needed totreat (NNT)for theuseof spironoLactonein
thetreatment of heartfaiuure with respect to aL-cause mortality?
@1MIN NDOCRINE
